

Figure S1. Follow-up information of patients with liver cancer in antitumor therapy subgroups. PFS in (A) group A and (B) group B. OS in (C) group A and (D) group B. TKIs, tyrosine kinase inhibitors; ICIs, immune checkpoint inhibitors; PFS, progression-free survival; OS, overall survival.

